DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation

Completed

Phase 2 Results

Summary of Purpose

This study will be conducted in male and female subjects aged 18 to 80 years, inclusive, with non-valvular AF and a CHADS2 Score of at least 1. Subjects will be treated on an outpatient basis. The subjects will be allocated randomly to the open-label warfarin or any double-blind DU-176b dosages. DU-176b will be administered orally for 12 weeks at two fixed doses. Warfarin will be used as active control. Warfarin...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 15 January 2015.

1 Oct 2007 10 Dec 2008 1 Oct 2008 1 Nov 2009 1 Jan 2015 15 Jan 2015
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Prevention
  • Endpoint: Safety Study
  • Intervention: Parallel Assignment

Contacts

Not available